• Please join IMMUNICUM at our
    Investor Event in Kalmar on June 13th

    An open and interactive evening with IMMUNICUM

    We kindly request you to RSVP with your full name. The RSVP will confirm your spot at the event. Registration for the session will close once capacity is reached.

    Confirm by RSVP
  • Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel

    Learn more

Immunicum is listed on NASDAQ Stockholm under the ticker IMMU

About us

Developing innovative cancer immunotherapies

We are on a journey towards the world’s first patient unique, off-the-shelf cancer treatment. Get to know the technology that will take us there.

Learn more